In Situ Slow‐Release Hydrogen Sulfide Therapeutics for Advanced Disease Treatments

作者：Yiqing Chen, Zhishan Chen, Xingzhong Chen, Shizhen Zhang, Shaoan Zhang, Qiyun Kang, Kaniyarakkal Sharafudeen, Huiwang Lian, S. Saravanakumar, Xinyue Zhang, Jialong Xu, Xiaoqin Zhu, Qingbin Zhang, Gang Han, Yang Li · 发表于：Small · 年份：2025 · DOI：10.1002/smll.202410909 · 被引用次数：8 · 研究领域：Sulfur Compounds in Biology、Obstructive Sleep Apnea Research、Nanoplatforms for cancer theranostics

Abstract Hydrogen sulfide (H 2 S) gas therapygarners significant attention for its potential to improve outcomes in various disease treatments. The quantitative control of H 2 S release is crucial for effective the rapeutic interventions; however, traditional researchon H 2 S therapy frequently utilizes static release models and neglects the dynamic nature of blood flow. In this study, we propose a novel slow‐release in‐situ H 2 S release model that leverages the dynamic hydrolysis of H 2 S donorswithin the bloodstream. Calcium sulfide nanoparticles (CaS NPs) withmicrosolubility characteristics exhibit continuous H 2 S release, surpassing 24 h at normal blood flow velocities. The extended‐release profile demonstrates superior potential in aligning with the bell‐shapedpharmacological effect of H 2 S, compared to NaHS. Moreover, we synthesisedrare earth‐doped CaS NPs (CaS: Eu 2+ , Sm 3+ NPs) tha texhibit persistent luminescence, enabling visualisation of the continuous H 2 S release in trials. Our results demonstrate that lowdose CaS: Eu 2+ , Sm 3+ NPs significantly reduces seizureduration to 1.2 ± 0.7 minutes, while high dose effectively suppresses colontumor growth with a tumor inhibition rate of 54%. Remarkably, these findings closely resemble endogenous H 2 S levels in treating epilepsy and tumors. This innovative slow‐release, in‐situ H 2 S the rapeutic approach via hydrolysis rejuvenates the development of H 2 S‐basedtherapeutics.